ClinicalThought™
Interact with experts and peers.

Recent Posts

10 of 38 Shown
  • My Take on the Guidance From AASLD/IDSA for Managing Treatment-Experienced Patients With Genotype 3 HCV Infection and Cirrhosis

    Ira M. Jacobson MD - 11/5/2014 2 comments / Last Comment: 11/20/2014
    When treatment-experienced patients with genotype 3 HCV infection and evidence of advanced liver disease seek care, it’s important to treat them now, even if evidence defining the best regimen is limited.
  • My Take on the Guidance From AASLD/IDSA for Treating PI-Experienced Patients With Genotype 1 HCV Infection

    Norah Terrault MD, MPH - 11/4/2014 1 comment / Last Comment: 11/16/2014
    In this rapidly evolving treatment environment, the best available regimen may not yet have been incorporated into the expert guidance.
  • My Take on the Guidance From AASLD/IDSA for Managing Treatment-Experienced Patients With Genotype 1 HCV Infection and Cirrhosis

    Nezam H. Afdhal MD, FRCPI - 11/4/2014 6 comments / Last Comment: 12/9/2014
    New regimens are becoming available for genotype 1 HCV infection that offer more data and apparently better efficacy than previously recommended regimens in patients with cirrhosis who have experienced previous treatment failure.
  • My Take on the Guidance From AASLD/IDSA for Treating Patients With Genotype 2 HCV Infection

    Norah Terrault MD, MPH - 11/4/2014
    The AASLD/IDSA HCV guidance is straight forward regarding treatment-naive patients with genotype 2 HCV infection, but there are a few considerations to keep in mind.
  • All-Oral Therapy for HCV: Rewriting the Course of the Disease

    Nancy Reau MD - 11/3/2014 5 comments / Last Comment: 12/9/2014
    All-oral HCV therapies are erasing the importance of traditional obstacles to cure
  • How Does the AASLD/IDSA HCV Guidance Weigh in on Management of HIV Coinfection?

    Douglas T. Dieterich MD - 10/9/2014 1 comment / Last Comment: 10/24/2014
    There is great interest in offering coinfected patients the same opportunity for cure as monoinfected patients. The AASLD/IDSA guidance has developed recommendations aimed at maximizing cure in different populations of coinfected individuals.
  • My Take on the Guidance From AASLD/IDSA for Treating Interferon-Ineligible Patients With Genotype 1 HCV Infection

    Paul Y. Kwo MD - 10/9/2014 3 comments / Last Comment: 10/24/2014
    Historically, evaluating patients for interferon eligibility was critical. Today, interferon-free regimens are evolving and soon they will be standard practice for even the most difficult-to-treat disease.
  • Delivering on the Promise: Maximizing SVR in the Real World

    Jordan J. Feld MD, MPH - 10/6/2014 10 comments / Last Comment: 11/5/2014
    Delivering the successes of recent HCV therapy trials to the real world will take some work, but here is how it can be achieved.
  • Prioritizing Patients for HCV Therapy: The Case for Treating Before Advanced Disease

    Nancy Reau MD - 9/23/2014 4 comments / Last Comment: 10/24/2014
    Despite remarkable advances in curative treatments for HCV, many patients are being denied insurance coverage, as priority access to these costly medications is given to those with advanced disease.
  • Are New HCV Therapies Ready for Use in Transplant Patients?

    Paul Y. Kwo MD - 7/10/2014 4 comments / Last Comment: 9/18/2014
    Paul Y. Kwo, MD, introduces some of the topics that will be discussed in an upcoming symposium in San Francisco.
10 of 38 Shown
Show 10 More
Loading...